UCB’S IMPRESSIVE FULL DECK (ADD; 15% UPSIDE)
27/11/20 -"After being range-bound for the most part of 2019, UCB (Add, Belgium) gained momentum in October 2019 when the company made an acquisition in the fast-growing (c.10% p.a.) myasthenia gravis/MG space ..."
Pages
59
Language
English
Published on
27/11/20
You may also be interested by these reports :
30/10/26
Investors hailed the Q3 profitability beat and the announcement of a cost savings initiative. The generic erosion of some CVRM medicines was ...
30/10/26
The Q3 beat was impressive and a guidance upgrade to boot cheered up investors. As usual, the all-important immunology medicine Dupixent remained a ...
29/10/26
The Q3 EBITDA was somewhat ahead of expectations, unlike sales. While lower demand in Spain and loss of exclusivity in Japan impaired Bilastine’s ...
29/10/26
After increasing both our DCF and NAV estimates by >20% (discussed in the respective sections), we maintain a Reduce recommendation with c.2% ...